An early glimpse at azacitidine plus venetoclax for myelodysplastic syndromes
Mené sur 23 patients atteints d'un syndrome myélodysplasique à haut risque de récidive ou d'une leucémie myélomonocytaire chronique (durée médiane de suivi : 13,2 mois), cet essai de phase I/II évalue la dose maximale tolérée de l'azacitidine en combinaison avec le vénétoclax
Myelodysplastic syndromes, chronic myelomonocytic leukaemia, and acute myeloid leukaemiacomprise a spectrum of heterogenous myeloid diseases characterised by abnormal haematopoiesis,a block in differentiation, and haematopoietic insufficiency resulting in cytopenias.These multiclonal processes show considerable biologic, phenotypic, genetic, and clinicaloverlap. In recognition of this continuum, WHO has recently renamed the former categoryof myelodysplastic syndromes with excess blasts-2 (defined as having ≥10% and <20%bone marrow blasts) to “myelodysplastic syndromes/acute myeloid leukaemia”. Giventhe biological similarities, treatments for acute myeloid leukaemia have been commandeeredfor patients with myelodysplastic syndromes and chronic myelomonocytic leukaemia,albeit with modified doses or schedules to accommodate lower bone marrow reservesin the latter conditions.
The Lancet Haematology , commentaire, 2021